Хохлов

Список литературы

479.TargetHunter[Электронныйресурс].–Режимдоступа:www.cbligand. org/TargetHunter/.

480.TarPred[Электронныйресурс].–Режимдоступа:202.127.19.75:5555/.

481.The European XFEL Consortium [Электронный ресурс]. – Режим доступа: www.xfel.eu/organization/partner_countries/index_eng.html.

482.The Rules Governing Medicinal Products in the European Union.eu Guidelines for Good Manufacturing Practices for Medicinal Products for Human andVeterinaryUse[Электронныйресурс]/EudraLex.–V.4.–Режимдоступа: ec.europa.eu/health/documents/eudralex/vol–4/index_en.htm.

483.Technology Transfer (Second Edition). Good Practice Guide [Текст] / ISPE, 2014. – 84 р.

484.TechnologyTransfer.GoodPracticeGuide[Текст]/ISPE,2003.–124р.

485.The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality – M4Q(R1). Quality Overall Summary of Module 3: Quality [Электронный ресурс]. – 2002. – Режим доступа: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R1_ Quality/M4Q_R1_.pdf.

486.The Tuskegee Timeline [Электронный ресурс]. – Режим доступа: www.cdc.gov/tuskegee/timeline.htm.

487.Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt [Электронный ресурс]. – U. S. National Library of Medicine. – Режим доступа: clinicaltrials.gov/ct2/show/NCT01722604.

488.Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea (MTZG) [Электронный ресурс]. – U. S. National Library of Medicine. – Режим доступа: clinicaltrials.gov/ct2/show/ NCT01513863.

489.Todeschini,R.HandbookofMolecularDescriptors[Tекст]:R.Todeschini, V. Consonni, R. Mannhold. – Weinheim: Wiley, 2008. – 688 p.

490.Tothfalusi, L. Sample Sizes for Designing Bioequivalence Studies for

Highly Variable Drugs [Tекст] / L. Tothfalusi, L. Endrenyi // The Journal of Pharmacy and Pharmaceutical Sciences. – 2012. – V. 15, №1. – p. 73–84.

491.Tropsha,A.BestpracticesforQSARmodeldevelopment,validation,and exploitation [Tекст] / A. Tropsha // Molecular Informatics. – 2010. – V. 29. – p. 476–488.

492.Trosset, J.Y. In Silico Drug–Target Profiling [Tекст] / J. Y. Trosset, C. Cavé // Methods in Molecular Biology. – 2019. – V. 1953. – p. 89–103.

493.Tyson, J.J. Modeling the dynamic behavior of biochemical regulatory networks [Tекст] / J.J. Tyson, T. Laomettachit, P. Kraikivski // Journal of Theoretical Biology. – 2019. – V. 462. – p. 514–527.

494.Ursu, O. Understanding drug–likeness [Tекст] / O. Ursu, A. Rayan, A.Goldblum[etal.]//WileyInterdisciplinaryReviews:ComputationalMolecular Science. – 2011. – №1. – р. 760–781.

495.Usha, T. Recent Updates on Computer–aided Drug Discovery: Time for a Paradigm Shift [Текст] / T. Usha, D. Shanmugarajan, A.K. Goya [et al.] // Current Topics in Medicinal Chemistry. – 2017. – V. 30, №17. – p. 3296–3307.

496.VanNorman,G.A.DrugsandDevices.JACC[Текст]/G.A.VanNorman

//Basic to Translational Science. – 2016. – V. 1. – р. 399–412.

391

Промышленная фармация. Путь создания продукта

497.Van de Waterbeemd, H.ADMET in silico modelling: towards prediction paradise? [Текст] / H. Van de Waterbeemd, E. Gifford // Nature Reviews Drug Discovery. – 2003. –V. 2, №3. – р. 192–204.

498.Vladimir Poroikov. Google Scholar profile [Электронный ресурс]. –

Режим доступа: scholar.google.ru/citations?hl=ru&user=F13hIJMAAAAJ&vi ew_op=list_works&sortby=pubdate.

499.Verma, S. Target based drug design – a reality in virtual sphere [Текст] / S. Verma, Y.S. Prabhakar // Current Medicinal Chemistry. – 2015. – V. 22, №13.

– р. 1603–1630.

500.Vil, V.A. Peroxides with Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions [Текст] / V.A. Vil, I.A.Yaremenko,A.I. Ilovaisky [et al.] // Molecules. – 2017. –V. 22, №11. – р. 1881.

501.Voigt, J.H. Comparison of the NCI open database with seven large

chemical structural databases [Текст] / J.H. Voigt, B. Bienfait, S. Wang [et al.] // Journal of Chemical Information and Computer Sciences. – 2001. – V. 41, №3. – р. 702–712.

502.Wade, R.C. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds [Текст]/R.C.Wade,K.J.Clark,P.J.Goodford//JournalofMedicinalChemistry.

–1993. – V. 1, № 36. – р. 140–147.

503.Wagner, J.A dynamic map for learning, communicating, navigating and improvingtherapeuticdevelopment[Текст]/J.Wagner,A.M.Dahlem,L.D. Hudson [et al.] // Nature Reviews Drug Discovery. – 2018. –V. 17, №2. – р. 150–153.

504.Walters, W.P. Designing screens: how to make your hits a hit [Текст] /

W.P. Walters, M. Namchuk // Nature Reviews Drug Discovery. – 2003. – V. 2, №4. – р. 259–266.

505.Wang, G. Molecular docking for drug discovery and development: a widely used approach but far from perfect [Текст] / G. Wang, W. Zhu // Future Medicinal Chemistry. – 2016. – V. 8, №14. – р. 1707–1710.

506.Wang,X.Structure-BasedDrugDesignStrategiesandChallenges[Текст]

/X. Wang, K. Song, L. Li [et al.] // Current Topics in Medicinal Chemistry. – 2018. – V. 18, №12. – р. 998–1006.

507.Webb, A. Process Transfer to Contract Manufacturing Organizations: A Case Study on Process Development Support Past RegulatoryApproval [Текст] / A. Webb, D.H. Reifsnyder, J. Bender// Pharmaceutical Engineering. – 2010. – V. 30, №4. – p. 46–52.

508.Wermuth,C.G.Similarityindrugs:reflectionsonanaloguedesign[Текст]

/C.G. Wermuth // Drug Discovery Today. – 2006. – V. 11, №7–8. – р. 348–354.

509.What are the phases of clinical trials? [Электронный ресурс] // AmericanCancerSociety.–2017.–Режимдоступа:www.cancer.org/treatment/ treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of- clinical-trials.html.

510.WHO Expert Committee on Specifications for Pharmaceutical Preparations. Pharmaceutical development of multisource (generic) pharmaceutical products – point to consider [Текст] // WHO Technical Report Series. – № 970, Annex 3. – 2012. – p. 91–121.

392

Список литературы

511.WHO Guidelines on transfer of technology in pharmaceutical manufacturing.[Текст]//WHOTechnicalReportSeries.–2011.–№961,Annex

7.– p. 286–309.

512.Wickremsinhe, E.R. Stereoselective Metabolism of Prasugrel in Humans

Using a Novel Chiral Liquid Chromatography–Tandem Mass Spectrometry Method [Текст] / E.R. Wickremsinhe, Y. Tian, K.J.ruterbories [et al.] // Drug Metobalism and Disposition. – 2007. – V. 35, №6. – p. 917–921.

513.Williams, A.J. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation [Текст] / A.J. Williams, S. Ekins, V. Tkachenko // Drug Discovery Today. – 2012. – V. 17, №13–14. – р. 685−701.

514.Wirth, D.D. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine [Текст] / D.D. Wirth, S.W. Baertschi, R.A. Johnson [et al.] // Journal of Pharmaceutical Sciences. – 1998. – №1. – p. 31–39.

515.Wright, Z.V.F. Structure–based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin[Текст]/Z.V.F.Wright,N.C.Wu,R.U.Kadam[etal.]//Bioorganic

&Medicinal Chemistry Letters. – 2017. – V. 27, №16. – р. 3744–3748.

516.Wu, F. Network motifs modulate druggability of cellular targets [Текст]

/F. Wu, C. Ma, C. Tan // Scientific Reports. – 2016. – №6. – Режим доступа: www.nature.com/articles/srep36626.

517.Wu, H. Numerical discretization–based estimation methods for ordinary differential equation models via penalized spline smoothing with applications in biomedical research [Текст] / H. Wu, H. Xue,A. Kumar // Biometrics. – 2012. – V. 68, №2. – р. 344–352.

518.Zaharevitz, D.W. COMPARE: a web accessible tool for investigating

mechanisms of cell growth inhibition [Текст] / D.W. Zaharevitz, S.L. Holbeck, C. Bowerman [et al.] // Journal of Molecular Graphics and Modelling. – 2002. – V. 20, №4. – р. 297–303.

519.Zakharov, A.V. Quantitative prediction of antitarget interaction profiles for chemical compounds /A.V. Zakharov,A.A. Lagunin, D.A. Filimonov [et al.]

//Chemical Research in Toxicology. – 2012. – V. 25, №11. – р. 2378–2385.

520.Zhang, Y. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open–label,three–way,reference–replicatedcrossoverstudy[Текст]/Y.Zhang, X. Chen, Y. Tang [et al.] // Drug Design, Development and Therapy. – 2017. – №11. – р. 2109–2119.

521.ZINCdatabase[Электронныйресурс].–Режимдоступа:zinc.docking.

org/.

393